X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (96) 96
female (61) 61
index medicus (55) 55
male (51) 51
middle aged (42) 42
physics (38) 38
aged (37) 37
adult (33) 33
investigating or analysing materials by determining theirchemical or physical properties (31) 31
measuring (31) 31
testing (31) 31
hematology (30) 30
chemistry (26) 26
metallurgy (25) 25
peripheral vascular disease (22) 22
orvostudományok (20) 20
organic chemistry (16) 16
klinikai orvostudományok (14) 14
peptides (14) 14
venous thromboembolism (14) 14
animals (13) 13
human necessities (13) 13
neurosciences (13) 13
risk factors (13) 13
treatment outcome (13) 13
aged, 80 and over (12) 12
thrombosis (12) 12
abridged index medicus (11) 11
anticoagulants (11) 11
anticoagulants - adverse effects (11) 11
anticoagulants - therapeutic use (11) 11
prospective studies (11) 11
adding materials to fuels or fires to reduce smoke orundesirable deposits or to facilitate soot removal (10) 10
climate change mitigation technologies in the production orprocessing of goods (10) 10
cracking hydrocarbon oils (10) 10
firelighters (10) 10
fuels (10) 10
fuels not otherwise provided for (10) 10
general tagging of cross-sectional technologies spanning over several sections of the ipc (10) 10
general tagging of new technological developments (10) 10
hungary (10) 10
life sciences (10) 10
liquefied petroleum gas (10) 10
lubricants (10) 10
measuring electric variables (10) 10
measuring magnetic variables (10) 10
mineral waxes (10) 10
natural gas (10) 10
peat (10) 10
petroleum, gas or coke industries (10) 10
production of liquid hydrocarbon mixtures, e.g. by destructivehydrogenation, oligomerisation, polymerisation (10) 10
recovery of hydrocarbon oils from oil-shale, oil-sand, orgases (10) 10
reduction of greenhouse gas [ghg] emissions, related to energygeneration, transmission or distribution (10) 10
refining mixtures mainly consisting of hydrocarbons (10) 10
reforming of naphtha (10) 10
synthetic natural gas obtained by processes not covered bysubclasses c10g, c10k (10) 10
technical gases containing carbon monoxide (10) 10
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (10) 10
technologies or applications for mitigation or adaptation againstclimate change (10) 10
anticoagulants - administration & dosage (9) 9
double-blind method (9) 9
hemorrhage - chemically induced (9) 9
medicine, general & internal (9) 9
alzheimer's disease (8) 8
prophylaxis (8) 8
therapy (8) 8
thromboembolism (8) 8
warfarin (8) 8
adolescent (7) 7
amusements (7) 7
apolipoprotein e (7) 7
card, board, or roulette games (7) 7
care and treatment (7) 7
cohort studies (7) 7
diagnosis (7) 7
drug therapy (7) 7
games (7) 7
games not otherwise provided for (7) 7
indoor games using small moving playing bodies (7) 7
oncology (7) 7
pregnancy (7) 7
psychiatry (7) 7
risk (7) 7
sports (7) 7
video games (7) 7
acute disease (6) 6
alzheimer disease - genetics (6) 6
alzheimers-disease (6) 6
biochemistry & molecular biology (6) 6
breast neoplasms - radiotherapy (6) 6
cancer (6) 6
disease (6) 6
elméleti orvostudományok (6) 6
follow-up studies (6) 6
genotype (6) 6
hemorrhage (6) 6
management (6) 6
molecular-weight heparin (6) 6
patients (6) 6
pharmacology & pharmacy (6) 6
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (212) 212
Hungarian (38) 38
German (18) 18
French (13) 13
Finnish (8) 8
Norwegian (3) 3
Swedish (2) 2
Croatian (1) 1
Portuguese (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Anand, Sonia S and Eikelboom, John W and Connolly, Stuart J and Widimsky, Peter and Aboyans, Victor and Alings, Marco and Kakkar, Ajay K and Keltai, Katalin and Störk, Stefan and Zhu, Jun and Lopez-Jaramillo, Patricio and O'Donnell, Martin and Vinereanu, Dragos and Pogosova, Nana and Ryden, Lars and Fox, Keith A A and Misselwitz, Frank and Varigos, John D and Chen, Edmond and Branch, Kelley and Bangdiwala, Shrikant I and Hart, Robert G and Yusuf, Salim and CARTASEGNA, LUIS and VICO, MARISA and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and ZAIDMAN, CESAR and VOGEL, DANIEL and HRABAR, ADRIAN and CUNEO, CARLOS and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and BARBIERI, MARIA and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and SCHIAVI, LILIA BEATRIZ and INGARAMO, ADRIAN and BORDONAVA, ANSELMO PAULINO and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and ALBISU DI GENNERO, JUAN PABLO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and CARDONA, MARCELO and SARJANOVICH, RODOLFO JUAN and CUADRADO, JESUS and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and MAFFEI, LAURA ELENA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and VERHAMME, PETER and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and ABRANTES, JOSE ANTONIO and MANENTI, EULER and MAIA, LILIA and HERNANDES, MAURO and ROSSI DOS SANTOS, FABIO and ZIMMERMANN, SERGIO LUIZ and ABIB JR, EDUARDO and LEAES, PAULO and BOTELHO, ROBERTO and BRAILE, MARIA and IZUKAWA, NILO and TANAJURA, LUIZ FERNANDO and SERRANO JUNIOR, CARLOS VICENTE and NASI, LUIZ ANTONIO and TYTUS, RICHARD and PANDEY, SHEKHAR and LONN, EVA and CHA, JAMES and VIZEL, SAUL and BABAPULLE, MOHAN and LAMY, ANDRE and KIAII, BOB and BHARGAVA, RAKESH and MEHTA, PRAVINSAGAR and HILL, LAURIE and FELL, DAVID and LAM, ANDY and AL-QOOFI, FAISAL and PETRELLA, ROBERT and GLANZ, ANTHONY and NOISEUX, NICOLAS and ... and COMPASS Investigators and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The Lancet, ISSN 0140-6736, 01/2018, Volume 391, Issue 10117, pp. 219 - 229
Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | MANAGEMENT | THERAPY | OUTPATIENTS | CARDIOVASCULAR EVENT RATES | PREVENTION | RISK | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Carotid Artery Diseases - complications | Male | Peripheral Arterial Disease - complications | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Incidence | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Lower Extremity - surgery | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Myocardial Infarction - etiology | Rivaroxaban - therapeutic use | Carotid Artery Diseases - drug therapy | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Peripheral Arterial Disease - drug therapy | Carotid Artery Diseases - epidemiology | Morbidity | Factor Xa Inhibitors - therapeutic use | Stroke - etiology | Peripheral Arterial Disease - epidemiology | Factor Xa Inhibitors - adverse effects | Aged | Myocardial Infarction - prevention & control | Amputation - statistics & numerical data | Hemorrhage - chemically induced | Lower Extremity - blood supply | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Heart attacks | Medical imaging | Mortality | Clinical trials | Cardiovascular disease | Patients | Disease control | Evidence-based medicine | Carotid arteries | Disease prevention | Coronary vessels | Blood pressure | Carotid artery | Acute coronary syndromes | Thromboembolism | Health risk assessment | Cardiovascular Diseases | Factor Xa Inhibitors | Klinisk medicin | Hemorrhage | epidemiology | Rivaroxaban | administration & dosage | Combination | Amputation | Drug | drug therapy | chemically induced | complications | prevention & control | Peripheral Arterial Disease | etiology | Clinical Medicine | Myocardial Infarction | statistics & numerical data | blood supply | Carotid Artery Diseases | Platelet Aggregation Inhibitors | adverse effects | mortality | Lower Extremity | Dose-Response Relationship | therapeutic use | surgery
Journal Article
by Connolly, Stuart J and Dagenais, Gilles and Dyal, Leanne and Lanas, Fernando and O'Donnell, Martin and Dans, Anthony L and Ha, Jong-Won and Parkhomenko, Alexandr N and Lonn, Eva and Lisheng, Liu and Torp-Pedersen, Christian and Widimsky, Petr and Maggioni, Aldo P and Felix, Camilo and Hori, Masatsugu and Cook Bruns, Nancy and Anand, Sonia S and Varigos, John D and Fox, Keith A A and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and ZAIDMAN, CESAR and VOGEL, DANIEL and HRABAR, ADRIAN and SCHYGIEL, PABLO OMAR and CUNEO, CARLOS and LUQUEZ, HUGO and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and MONTANA, OSCAR and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and GARRIDO, MARCELO and INGARAMO, ADRIAN and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and CARDONA, MARCELO and GUZMAN, LUIS and CUADRADO, JESUS and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and ECTOR, BAVO and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and VRANCKX, PASCAL and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and PRECOMA, DALTON and ABRANTES, JOSE ANTONIO and MANENTI, EULER and REIS, GILMAR and SARAIVA, JOSE and MAIA, LILIA and HERNANDES, MAURO and ROSSI, PAULO and ZIMMERMANN, SERGIO LUIZ and RECH, RAFAEL and ABIB JR, EDUARDO and LEAES, PAULO and BOTELHO, ROBERTO and DUTRA, OSCAR and BRAILE, MARIA and IZUKAWA, NILO and NICOLAU, JOSE CARLOS and TANAJURA, LUIZ FERNANDO and MINELLI, CESAR and OLIVEIRA, LIVIA and DE CARVALHO CANTARELLI, MARCELO JOSE and TYTUS, RICHARD and PANDEY, SHEKHAR and CHA, JAMES and BABAPULLE, MOHAN and LAMY, ANDRE and SAUNDERS, KEVIN and KIAII, BOB and BHARGAVA, RAKESH and MEHTA, PRAVINSAGAR and HILL, LAURIE and FELL, DAVID and AL-QOOFI, FAISAL and BROWN, CRAIG and RICCI, JOSEPH A and GLANZ, ANTHONY and NOISEUX, NICOLAS and ... and COMPASS investigators and COMPASS Investigators and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The Lancet, ISSN 0140-6736, 01/2018, Volume 391, Issue 10117, pp. 205 - 218
Coronary artery disease is a major cause of morbidity and mortality worldwide, and is a consequence of acute thrombotic events involving activation of... 
PREVENTION | MEDICINE, GENERAL & INTERNAL | ORAL RIVAROXABAN | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Male | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Coronary Artery Disease - drug therapy | Morbidity | Factor Xa Inhibitors - therapeutic use | Factor Xa Inhibitors - adverse effects | Aged | Coronary Artery Disease - epidemiology | Myocardial Infarction - prevention & control | Hemorrhage - chemically induced | Anticoagulants | Aspirin | Stroke | Heart attacks | Mortality | Coronary artery | Clinical trials | Cardiovascular disease | Coronary artery disease | Disease control | Evidence-based medicine | Disease prevention | Coronary vessels | Acute coronary syndromes | Thromboembolism | Health risk assessment | Drug therapy | Heart diseases | Cardiovascular Diseases | Factor Xa Inhibitors | Klinisk medicin | Hemorrhage | epidemiology | Rivaroxaban | administration & dosage | Combination | Drug | drug therapy | chemically induced | prevention & control | Coronary Artery Disease | Clinical Medicine | Myocardial Infarction | Platelet Aggregation Inhibitors | adverse effects | mortality | Dose-Response Relationship | therapeutic use
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2018, Volume 378, Issue 7, pp. 615 - 624
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9792, pp. 740 - 740
... (b), Mariann Szarvas (a), Zoltan Boda (a) Author Affiliation: (a) 2nd Department of Medicine, University of Debrecen, Nagyerdei krt 98, 4012 Debrecen, Hungary (b... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | HEPARIN-INDUCED THROMBOCYTOPENIA | PLATELET ACTIVATION | ANTIPHOSPHOLIPID SYNDROME | Gangrene | Drug therapy
Journal Article
Journal Article
Physical Chemistry Chemical Physics, ISSN 1463-9076, 2017, Volume 19, Issue 27, pp. 17816 - 17826
In a multiscale modeling approach, we present computer simulation results for a rectifying bipolar nanopore at two modeling levels. In an all-atom model, we... 
SYNTHETIC CONICAL NANOPORES | MOLECULAR-DYNAMICS | NANOFLUIDIC DIODE | CALCIUM-CHANNELS | RYANODINE RECEPTOR | PHYSICS, ATOMIC, MOLECULAR & CHEMICAL | CHEMISTRY, PHYSICAL | IONIC CURRENT RECTIFICATION | MONTE-CARLO SIMULATIONS | ASYMMETRIC NANOPORES | BROWNIAN DYNAMICS | POISSON-NERNST-PLANCK
Journal Article
Journal Article
The European Physical Journal B, ISSN 1434-6028, 6/2013, Volume 86, Issue 6, pp. 1 - 9
Spontaneous synchronization of an ensemble of metronomes placed on a freely rotating platform is studied experimentally and by computer simulations. A striking... 
Condensed Matter Physics | Solid State Physics | Fluid- and Aerodynamics | Statistical and Nonlinear Physics | Physics, general | Statistical Physics, Dynamical Systems and Complexity | Physics | SYNCHRONIZATION | PHYSICS, CONDENSED MATTER | Computer simulation | Computer-generated environments
Journal Article
Thrombosis and haemostasis, ISSN 0340-6245, 2016, Volume 116, Issue 1, pp. 155 - 161
Edoxaban is a once-daily direct oral anticoagulant (DOAC). The Hokusai-VTE study revealed that, after initial treatment with heparin, edoxaban was non-inferior... 
Stroke, Systemic or Venous Thromboembolism | Coumarins | Anticoagulants | Edoxaban | Haemorrhage | Venous thromboembolism | RISK-FACTORS | coumarins | RIVAROXABAN | haemorrhage | edoxaban | CHALLENGES | DABIGATRAN | WARFARIN | venous thromboembolism | ORAL ANTICOAGULANTS | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY
Journal Article